Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus TOLAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus TOLAK.
GRIS-PEG vs TOLAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
TOLAK (tazarotene) is a retinoid prodrug that is converted to its active metabolite tazarotenic acid, which binds selectively to retinoic acid receptors (RARs) such as RARβ and RARγ; this modulates gene expression involved in cell proliferation, differentiation, and inflammation.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
Adults: 200 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
The terminal elimination half-life of fluorouracil is approximately 10-20 minutes due to rapid catabolism by dihydropyrimidine dehydrogenase. Clinically, this short half-life necessitates continuous infusion for sustained systemic exposure.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Tolak (fluorouracil) is primarily eliminated via metabolism; less than 10% is excreted unchanged in urine. Fecal excretion accounts for approximately 10-20% of the administered dose.
Category C
Category C
Antifungal
Antifungal